

# A Protein-Based Biosensor for Detecting Calcium by Magnetic Resonance Imaging

Harun F. Ozbakir, Austin D. C. Miller, Kiara B. Fishman, André F. Martins, Tod E. Kippin, and Arnab Mukherjee\*

Cite This: <https://doi.org/10.1021/acssensors.1c01085>

Read Online

ACCESS |


Metrics & More

Article Recommendations

Supporting Information

**ABSTRACT:** Calcium-responsive contrast agents for magnetic resonance imaging (MRI) offer a promising approach for noninvasive brain-wide monitoring of neural activity at any arbitrary depth. Current examples of MRI-based calcium probes involve synthetic molecules and nanoparticles, which cannot be used to examine calcium signaling in a genetically encoded form. Here, we describe a new MRI sensor for calcium, based entirely on a naturally occurring calcium-binding protein known as calprotectin. Calcium-binding causes calprotectin to sequester manganese ions, thereby limiting  $Mn^{2+}$  enhanced paramagnetic relaxation of nearby water molecules. We demonstrate that this mechanism allows calprotectin to alter  $T_1$  and  $T_2$  based MRI signals in response to biologically relevant calcium concentrations. The resulting response amplitude, i.e., change in relaxation time, is comparable to existing MRI-based calcium sensors as well as other reported protein-based MRI sensors. As a preliminary demonstration of its biological applicability, we used calprotectin to detect calcium in a lysed hippocampal cell preparation as well as in intact Chinese hamster ovary cells treated with a calcium ionophore. Calprotectin thus represents a promising path toward noninvasive imaging of calcium signaling by combining the molecular and cellular specificity of genetically encodable tools with the ability of MRI to image through scattering tissue of any size and depth.

**KEYWORDS:** magnetic resonance imaging, calcium imaging, genetically encoded reporters, neuroimaging,  $Mn^{2+}$  enhanced MRI




In the nervous system, calcium ions give rise to intracellular signals that modulate a wide range of biological functions including neural activity, gene expression, synaptic communication, and apoptosis.<sup>1,2</sup> Consequently, experimental imaging of calcium in living cells and organisms is a cornerstone technology for obtaining detailed, time-lapse information on neural signaling mechanisms.<sup>3–5</sup> High-resolution calcium imaging typically relies on fluorescent dyes and genetically encoded calcium indicators (GECIs), which in conjunction with multiphoton microscopy can detect activity in single cells up to depths of 1 mm in intact tissue.<sup>6–16</sup> However, the imaging volume typically accessible by optical methods ( $\sim 1\text{ mm}^3$ ) encompasses only a small fraction of the brain in most vertebrates.<sup>17–20</sup> Calcium signals can also be recorded from deeper tissues using endoscopes and specialized lenses, but these techniques cover a limited field of view and require invasive surgery to embed the imaging hardware inside tissues.<sup>21,22</sup> Among noninvasive modalities, magnetic resonance imaging (MRI) is unrivaled in its ability to access large volumes of intact tissue located at any arbitrary depth. Thus, MRI-based calcium sensors have the potential to uniquely complement optical indicators by enabling wide-field imaging of biological processes in deep tissues noninvasively. This vision has motivated the development of a versatile collection of small-molecule paramagnetic complexes, fluorinated agents, and superparamag-

netic iron oxide crystals that have evolved over the past two decades for imaging calcium by various MRI mechanisms including longitudinal ( $T_1$ ) and transverse ( $T_2$ ) relaxation, chemical exchange saturation transfer (CEST), and direct detection of  $^{19}\text{F}$  spins.<sup>23–40</sup> Regardless of the specific contrast mechanism, all reported MRI probes for calcium are synthetic molecules, which makes them incompatible with genetic technologies for *in vivo* delivery, stable long-term expression, and cell type specific targeting—key aspects that underpin the prolific success of genetically encoded calcium indicators derived from the green fluorescent protein (GFP).<sup>10</sup> While iron-containing enzymes such as cytochrome P450 and ferritin nanoparticles have been used to develop protein-based MRI sensors for functional imaging of neurotransmitters and kinase activity,<sup>41–46</sup> to the best of our knowledge, there are no reported examples of protein-based MRI probes for calcium imaging. Here, we describe the development of the first biomolecular MRI reporter for calcium, based on a novel manganese

Received: May 26, 2021

Accepted: August 6, 2021




**Figure 1.** Principle of calcium imaging with calprotectins. (A) Proposed mechanism of MRI contrast induced by sequestration of paramagnetic  $\text{Mn}^{2+}$  ions by calprotectin in the presence of calcium. (B) Percent change in  $T_1$  and  $T_2$  relaxation times obtained for a binary mixture of calprotectin (40, 100, and 200  $\mu\text{M}$ ) and  $\text{Mn}^{2+}$  (30, 75, and 150  $\mu\text{M}$ ) in response to saturating amounts of calcium (2 mM) in HEPES buffer 9; pH 7.4). (C)  $T_1$  and  $T_2$  weighted images of calcium (2 mM) induced MRI contrast obtained with a binary mixture of 200  $\mu\text{M}$  calprotectin and 150  $\mu\text{M}$   $\text{Mn}^{2+}$ . All MRI measurements were performed at 7 T. Error bars represent standard error of mean from 5 independent replicates.

metalloprotein, and demonstrate its utility for imaging calcium in a biological context.


## RESULTS AND DISCUSSION

Our sensor is based on calprotectin, an antimicrobial protein that is released by neutrophils to chelate essential transition metals (including paramagnetic  $\text{Mn}^{2+}$  ions), thus limiting their availability for pathogenic microorganisms in infection sites.<sup>47–50</sup> The calprotectin heterodimer coordinates  $\text{Mn}^{2+}$  using two histidine-rich motifs located at the interface of the two subunits.<sup>48,51–53</sup> Each subunit also contains a canonical EF-hand motif for binding calcium.<sup>54</sup> Early biochemical studies on calprotectin found that calcium ions are responsible for tuning its  $\text{Mn}^{2+}$  binding properties, allowing the protein to strongly bind  $\text{Mn}^{2+}$  ions only when calcium ions are also bound.<sup>52,55,56</sup> Based on calprotectin's unique ability to sequester  $\text{Mn}^{2+}$  ions and shield them from nearby water molecules specifically in response to calcium, we reasoned that it should be possible to adapt calprotectin for MRI-based detection of calcium. Specifically, we hypothesized that in the absence of calcium, a binary mixture of calprotectin and  $\text{Mn}^{2+}$  ions would effectively shorten the  $T_1$  and  $T_2$  relaxation times of water molecules due to paramagnetic relaxation enhancement from free (i.e., unbound)  $\text{Mn}^{2+}$ . In the presence of calcium, calprotectin would sequester free  $\text{Mn}^{2+}$  ions, limiting access to neighboring water molecules and consequently increase relaxation times in inverse proportion to the concentration of free  $\text{Mn}^{2+}$  ions remaining in solution (Figure 1A). To test our hypothesis, we cloned both subunits of human calprotectin in *E. coli* BL21 cells, substituting the single cysteine residue in each subunit with serine to avoid cross-linking during purification. We purified and reconstituted the 26 kDa heterodimer using metal-affinity chromatography and verified biochemical function by assaying for calcium-dependent  $\text{Mn}^{2+}$  binding using a fluorescent dye (Figure S1). Next, we incubated various concentrations of purified calprotectin with  $\text{Mn}^{2+}$  and measured changes in  $T_1$  and  $T_2$  relaxation times at high (7 T) magnetic field induced by saturating amounts ( $\sim 50$ -fold excess) of calcium. These experiments revealed a calcium-dependent increase in relaxation times ranging from  $20 \pm 4\%$  to  $95 \pm 4\%$  for  $T_1$  and  $56 \pm 14\%$  to  $201 \pm 2\%$  for  $T_2$  ( $N = 5$ ) (Figure 1B), thereby allowing calcium ions to be respectively visualized as darkening or brightening of MRI signals in standard

$T_1$  and  $T_2$  weighted images (Figure 1C). Relaxivity values of the  $\text{Mn}^{2+}$ -bound protein complex in the presence of calcium were measured as  $0.20 \pm 0.07 \text{ mM}^{-1} \text{ s}^{-1}$  ( $r_1$ ) and  $3.30 \pm 0.33 \text{ mM}^{-1} \text{ s}^{-1}$  ( $r_2$ ), which are substantially smaller than free  $\text{Mn}^{2+}$  relaxivity.<sup>57</sup> The lower relaxivity of  $\text{Mn}^{2+}$  in the bound state is consistent with previous studies that found the  $\text{Mn}^{2+}$  coordination environment in calprotectin to largely exclude water molecules.<sup>55</sup> Notably, the amplitude of  $T_1$  and  $T_2$  changes obtained with calprotectin are 2–6-fold larger than the peak response estimated for identical concentrations of metalloprotein-based MRI sensors (targeting dopamine,<sup>42</sup> serotonin,<sup>44</sup> protein kinase<sup>41</sup>) reported to date (Figure S2). To characterize calprotectin's contrast mechanism in greater detail, we performed relaxometric titrations by treating calprotectin with a range of  $\text{Mn}^{2+}$  concentrations and measuring  $T_1$  and  $T_2$  values in the presence or absence of excess calcium. In calcium-free conditions, we observed a consistent decrease in  $T_1$  as the amount of  $\text{Mn}^{2+}$  was increased from 0 to 40  $\mu\text{M}$  (corresponding to 0–1 molar equiv protein). In contrast, when calcium ions were present, the extent of  $T_1$  change was significantly smaller ( $p < 0.01$ ,  $N = 5$ ) in the range of 10–40  $\mu\text{M}$   $\text{Mn}^{2+}$  (Figure 2A). We detected a similar trend in  $T_2$  values, which decreased with increasing concentrations of  $\text{Mn}^{2+}$  in the absence of calcium but displayed a significantly smaller change when calcium ions were available (Figure 2B). By fitting the measured  $T_1$  changes to binding isotherms, we determined that calcium elicits  $\sim 35$ -fold increase ( $K_d(-\text{Ca}) = 49.7 \pm 8.0 \mu\text{M}$ ,  $K_d(+\text{Ca}) = 1.42 \pm 0.42 \mu\text{M}$ ,  $p = 0.0003$ ,  $N = 5$ ) in calprotectin's binding affinity for  $\text{Mn}^{2+}$ , consistent with results from previous spectroscopic and calorimetric studies (Figure 2C and Table S1).<sup>52,56</sup> To further probe calprotectin's MRI properties, we introduced alanine substitutions in calprotectin's histidine-rich motifs to examine whether the calcium response is altered by changes in the  $\text{Mn}^{2+}$  coordination environment.<sup>52,54,55</sup> We examined the resulting variants using relaxometry (Figure S3) and found one mutant (His<sub>3</sub>Asp  $\rightarrow$  Ala<sub>4</sub>) that displayed lower  $\text{Mn}^{2+}$  affinity in the calcium-free state ( $K_d = 184.3 \pm 43.6 \mu\text{M}$ ) relative to wild-type calprotectin, leading to a modest but statistically significant increase ( $N = 3$ ,  $p = 0.005$ ) in overall calcium-induced fold change in relaxation time (Figure 2C,D and Table S2). Finally, we assessed the selectivity of calprotectin's MRI response toward calcium by incubating a mixture of calprotectin and  $\text{Mn}^{2+}$  ions with magnesium (50-fold excess), representing the



**Figure 2.** *In vitro* MRI relaxometry of calprotectin-based  $\text{Ca}^{2+}$  sensors. In the presence of calcium (2 mM), (A)  $T_1$  and (B)  $T_2$  relaxation times exhibit a significantly smaller decrease with increasing  $\text{Mn}^{2+}$  concentrations due to  $\text{Mn}^{2+}$  sequestration by calprotectin. The solid lines represent best fits to equilibrium binding isotherms. (C) Dissociation constants for  $\text{Mn}^{2+}$  binding to calprotectin (CP) and His<sub>3</sub>Asp variant (mut.) in the presence and absence of saturating calcium (2 mM), estimated from model-fitting of  $T_1$  titration results. (D) Calcium-induced percent change in  $T_1$  and  $T_2$  for calprotectin and the His<sub>3</sub>Asp mutant. (E) Calprotectin does not produce a change in  $T_1$  and  $T_2$  values or (F) detectable  $T_1$  and  $T_2$  weighted MRI contrast in response to saturating amounts of  $\text{Mg}^{2+}$  (2 mM). For all experiments, protein and calcium concentrations were 40  $\mu\text{M}$  and 2 mM, respectively.  $\text{Mn}^{2+}$  was either titrated from 0 to 30  $\mu\text{M}$  (A,B) or used at 30  $\mu\text{M}$  (D–F). Relaxation rates were measured at 7 T. Error bars represent standard error of mean from 3–5 independent replicates. \* denotes  $p < 0.05$  and n.s. indicates  $p > 0.05$  (Student's *t* test).



**Figure 3.** MRI-based sensing of biologically relevant calcium concentrations. (A) Percent change in  $T_1$  and  $T_2$  relaxation times in response to calcium concentrations spanning 0.1  $\mu\text{M}$  to 1 mM. Calprotectin and  $\text{Mn}^{2+}$  concentrations were 40  $\mu\text{M}$  and 30  $\mu\text{M}$ , respectively. (B) Percent change in relaxation times obtained by adding calprotectin (40  $\mu\text{M}$ ) and  $\text{Mn}^{2+}$  (30  $\mu\text{M}$ ) to a hippocampal cell lysate preparation treated with biologically relevant concentrations of calcium (1, 5, and 24  $\mu\text{M}$ ). (C) Change in  $T_1$  elicited by stimulating calcium entry in Chinese hamster ovary (CHO) cells lentivirally transduced with calprotectin-expressing vectors and treated with 10  $\mu\text{M}$  calcimycin, a calcium ionophore. As ionophore treatment by itself alters cellular  $T_1$ , all values are normalized to  $T_1$  values measured concurrently in identically treated CHO cells that have not been transduced to express calprotectin. Relaxation rates were measured at 7 T. Error bars represent standard error of mean from 3–5 independent replicates. \* denotes  $p < 0.05$  and \*\* indicates  $p < 0.01$  (Student's *t* test).

most abundant divalent cation found in cells. No significant change in  $T_1$  or  $T_2$  values could be detected under these conditions

( $p \geq 0.2$ ,  $N = 4$ ) (Figure 2E,F). Next, we established the dynamic range over which calcium ions can be sensed by calprotectin. For

these experiments, we fixed the amount of calprotectin and  $\text{Mn}^{2+}$  at 40 and 30  $\mu\text{M}$ , respectively, and measured  $T_1$  and  $T_2$  changes in buffered solutions consisting of calprotectin titrated with varying concentrations of calcium. In these settings, we detected an  $18.7 \pm 2.5\%$  ( $p = 0.007$ ,  $N = 3$ ) increase in  $T_1$  and a  $77.5 \pm 1.5\%$  ( $p = 1.0 \times 10^{-4}$ ,  $N = 3$ ) increase in  $T_2$  over calcium concentrations spanning the full biologically relevant range of (0.1–100  $\mu\text{M}$ ) (Figures 3A and S4). Taken together, our results indicate that calprotectin can be used to detect biologically relevant calcium changes based on an increase in  $T_1$  and  $T_2$  relaxation times triggered by calcium-induced binding to free  $\text{Mn}^{2+}$ , which leads to their sequestration in a low relaxivity state.

Next, as a precursor to calcium imaging in mammalian cells, we examined the sensor's calcium response in cellular conditions using intracellular lysates prepared from a mouse hippocampal cell line (HT-22). Similar cell lysate preparations have been previously used for *in vitro* validation of protein-based MRI sensors.<sup>41</sup> We supplemented the cell lysate with purified calprotectin and manganese chloride and then measured changes in relaxation times following treatment with calcium concentrations relevant to neural activity. In this cellular milieu, calcium concentrations as low as 5  $\mu\text{M}$  were found to induce a significant increase in  $T_1$  ( $7.0 \pm 1.8\%$ ,  $p = 0.02$ ,  $N = 4$ ) and  $T_2$  ( $9.1 \pm 1.0\%$ ,  $p = 0.0015$ ,  $N = 4$ ) (Figure 3B), while no change was detected when calcium was added to control lysates containing  $\text{Mn}^{2+}$  but lacking calprotectin ( $p > 0.2$ ,  $N = 3$ ) (Figure S5). Importantly, the  $T_1$  and  $T_2$  changes obtained with calprotectin are comparable to the calcium response reported for existing  $\text{Gd}^{3+}$  and  $\text{Mn}^{3+}$  based calcium probes (Table S3) and correspond to signal amplitudes that can be reliably detected *in vivo* by MRI techniques<sup>35,42,45,58</sup> already established for functional brain imaging.

Finally, we incorporated calprotectin in a polycistronic lentiviral construct, which was used to transduce a Chinese hamster ovary (CHO) cell line to establish stable expression from a strong CMV promoter. We delivered  $\text{Mn}^{2+}$  to cells by direct supplementation in the culture medium (Figure S6) and stimulated calcium entry by the addition of a calcium ionophore (calcimycin) in the presence or absence of extracellular calcium (5 mM). We performed  $T_1$  measurements on pelleted cells based on procedures established in our earlier work.<sup>59</sup> To control for nonspecific  $T_1$  changes arising from ionophore treatment, wild type CHO cells were also treated with calcimycin and imaged concurrently under identical conditions. In the presence of calcium, calprotectin-expressing cells were found to exhibit a  $22 \pm 4\%$  increase in  $T_1$  compared to control cells ( $p = 0.011$ ), whereas no change in  $T_1$  could be detected when either calcium or calcimycin was omitted from the medium ( $p > 0.7$ ) (Figures 3C and S7). Taken together with our results from the hippocampal preparation, these observations indicate that calprotectin may be used for MR imaging of calcium activity to detect changes from the resting-state ( $\sim 50$ –100 nM in neurons) to tens of micromolar concentration, which may be reached in stimulation paradigms involving electrical neuromodulation,<sup>60</sup> seizures,<sup>61,62</sup> and excitotoxic injury.

## CONCLUSIONS

Our findings represent the first example of a genetic construct for imaging calcium with MRI. The observed changes in  $T_1$  and  $T_2$  relaxation in response to calcium binding are comparable to most synthetic calcium probes (Table S3) and exceed that of previous protein-based MRI biosensors (Figure S2). Future work will focus on expressing calprotectin in neuronal cell lines,

primary neurons, and eventually *in vivo*, which will allow whole-brain imaging of calcium activity with the added benefit of being able to probe specific cell populations by genetic targeting. To this end, a preliminary assessment of the feasibility of applying calprotectins *in vivo* may be drawn by comparing with ManICS1, a synthetic (i.e., nongenetic)  $\text{Mn}^{2+}$  based calcium probe that was recently used to obtain the first measurements of intracellular calcium signals by MRI.<sup>35</sup> In this work, brain regions were acutely loaded with ManICS1 and stimulated by  $\text{K}^+$  infusion, which elicited a maximum  $T_1$  weighted signal change of  $5.8 \pm 1.2\%$ . Notably, both ManICS1 and calprotectin exhibit similar  $\text{IC}_{50}$  values for calcium binding (Table S3 and Figure 3A). However, calcium binding induces a larger relaxivity change in the calprotectin/ $\text{Mn}^{2+}$  sensor system ( $5.6$  to  $0.2 \text{ mM}^{-1} \text{ s}^{-1}$ ) compared to ManICS1 ( $3.6$  to  $5.1 \text{ mM}^{-1} \text{ s}^{-1}$ ). Given the successful implementation of ManICS1 for *in vivo* imaging, we therefore think that it should be possible in principle to adapt calprotectin-based sensors for imaging of calcium signals in the brain. However, practical challenges related to  $\text{Mn}^{2+}$  transport, background relaxation in brain tissue, reporter gene expression, and detection sensitivity will need to be addressed. Accordingly, we envision several areas of future development related to the application of calprotectins in animal models. First,  $\text{Mn}^{2+}$  dosing should be carefully optimized to minimize toxicity as well as ensure effective delivery to brain regions of interest. Several techniques for transporting  $\text{Mn}^{2+}$  (typically in quantities of tens of nanomoles, corresponding to intracellular concentrations of 35–93  $\mu\text{M}$  in the rodent brain<sup>63</sup>) with minimum acute toxicity have already been established in the context of  $\text{Mn}^{2+}$  enhanced MRI (MEMRI). These techniques include oral delivery, intraperitoneal administration, systemic injection, transcranial diffusion, and direct infusion in the cerebrospinal fluid.<sup>64–66</sup> Although  $\text{Mn}^{2+}$  can passively enter the brain parenchyma, transient and reversible opening of the blood brain barrier (e.g., using focused ultrasound) may be employed to augment the amount of  $\text{Mn}^{2+}$  transported.<sup>67</sup> A second challenge also related to  $\text{Mn}^{2+}$  delivery involves cell-type dependent variations in  $\text{Mn}^{2+}$  transport as well as increased  $\text{Mn}^{2+}$  flux (through calcium channels) in response to neural activity. The latter mechanism in fact serves as the basis for mapping activated brain regions by a technique known as activity-induced  $\text{Mn}^{2+}$  dependent MRI (AIM).<sup>68–70</sup> One potential approach for offsetting variabilities arising from cell-specific and activity-dependent changes in  $\text{Mn}^{2+}$  movement could be to co-express calprotectin with DMT1, a  $\text{Mn}^{2+}$  transporter, which is also used as an MRI reporter based on its ability to constitutively transport  $\text{Mn}^{2+}$  in cells.<sup>71,72</sup> Furthermore, because intracellular  $\text{Mn}^{2+}$  clears slowly from the brain (on the order of days), it may be feasible to implement calprotectins in conjunction with AIM. This could be done by time-locking calprotectin expression (e.g., using Cre-lox or TetTag transgenic models) to a temporal window that follows the AIM segment without further  $\text{Mn}^{2+}$  infusion. With judicious controls as well as detailed knowledge of calprotectin's response kinetics, such a multiparametric approach to functional MRI could reveal complementary insights on brain activity. Finally, although  $T_1$  weighted signal changes as small as  $\sim 1\%$  have been reliably measured *in vivo* using protein-based neurotransmitter sensors,<sup>42,45,58</sup> statistical fidelity of calcium detection can be greatly enhanced by optimizing calprotectins for a larger response amplitude. This can be achieved by protein engineering to increase calcium and  $\text{Mn}^{2+}$  binding affinities (in the calcium-bound state), ideally to sub- $\mu\text{M}$   $K_d$ (s). Improved  $\text{Mn}^{2+}$  binding will also have the added advantage of minimizing

competition from other  $Mn^{2+}$  sequestering molecules such as ATP and certain proteins (e.g., glutamine synthetase), which typically exhibit weaker but non-negligible  $Mn^{2+}$  affinity ( $\sim$ tens of  $\mu M$ ) compared to calprotectin.<sup>73</sup> These efforts are likely to benefit from the ability to utilize molecular engineering techniques such as directed evolution, which have been remarkably successful in expanding the toolbox of fluorescent calcium indicators<sup>10</sup> as well as developing new MRI reporters based on metalloproteins.<sup>42,74–77</sup> In summary, as the first biomolecular reporter for sensing calcium by MRI, calprotectin is a promising step in the ambitious path toward understanding how neural circuits and networks distributed throughout the mammalian brain coordinate to process information and generate behavior.

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acssensors.1c01085>.

Figures depicting biochemical purification and functional validation of calprotectin, analyte-induced percent change in relaxation times for published metalloprotein-based MRI sensors, relaxometric titration of His<sub>3</sub>Asp variant in the presence and absence of calcium, voxel-wise  $T_1$  and  $T_2$  response of calprotectin-based calcium sensor, calcium imaging in HT-22 cell lysates,  $Mn^{2+}$  uptake and toxicity in model mammalian cells, calcium imaging in CHO cells transduced with calprotectin and treated with a  $Ca^{2+}$  ionophore (calcimycin); tabulated values of  $Mn^{2+}$  binding affinity, and MRI response of published nongenetic calcium sensors, materials and methods; gene sequences of all constructs used in this work (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

**Arnab Mukherjee** – Department of Chemical Engineering, Biomolecular Science and Engineering, Department of Chemistry, Neuroscience Research Institute, and Center for Bioengineering, University of California, Santa Barbara, California 93106, United States; [orcid.org/0000-0003-3571-8015](https://orcid.org/0000-0003-3571-8015); Phone: (805) 893-5137; Email: [arnabm@ucsb.edu](mailto:arnabm@ucsb.edu)

### Authors

**Harun F. Ozbakir** – Department of Chemical Engineering, University of California, Santa Barbara, California 93106, United States

**Austin D. C. Miller** – Biomolecular Science and Engineering, University of California, Santa Barbara, California 93106, United States

**Kiara B. Fishman** – Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, California 93106, United States

**André F. Martins** – Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy and Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, Eberhard Karls University of Tübingen, Tübingen 72076, Germany; [orcid.org/0000-0002-0171-0261](https://orcid.org/0000-0002-0171-0261)

**Tod E. Kippin** – Neuroscience Research Institute and Psychology and Brain Sciences, University of California, Santa Barbara, California 93106, United States

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acssensors.1c01085>

## ■ Author Contributions

AM conceived the study. HFO and AM designed experiments with inputs from AFM and TEK. HFO performed all experiments with help from ADCM and KBF who assisted in biochemical studies. HFO and AM analyzed data and wrote the manuscript with inputs from all authors. AM supervised the research.

## ■ Notes

The authors declare no competing financial interest.

Preprint information: Harun F. Ozbakir, Austin D. C. Miller, Kiara B. Fishman, André F. Martins, Tod E. Kippin, Arnab Mukherjee. A protein-based biosensor for detecting calcium by magnetic resonance imaging. *bioRxiv* 2021. DOI [10.1101/2021.02.04.429691](https://doi.org/10.1101/2021.02.04.429691). (last accessed 07/10/2021).

## ■ ACKNOWLEDGMENTS

We thank members of the Mukherjee lab for helpful discussions. We are grateful to Prof. Elizabeth Nolan (MIT) for introducing us to calprotectins. We thank Prof. Mikhail Shapiro (Caltech) for insightful discussions on MRI and calcium imaging. This work was supported by the California NanoSystems Institute (University of California, Santa Barbara), a NARSAD Young Investigator Award from the Brain and Behavior Research Foundation, and a National Institutes of Health R35 Maximizing Investigators' Research Award (MIRA) and an R03 Imaging – Science Track Award for Research Transition (I/STAR) (to AM). HFO gratefully acknowledges support from the Errett Fisher Foundation. Finally, we extend our gratitude to the anonymous reviewers whose thorough analysis greatly helped in strengthening this work.

## ■ REFERENCES

- (1) Simons, T. J. B. Calcium and neuronal function. *Neurosurg. Rev.* **1988**, *11*, 119–129.
- (2) Brini, M.; Cali, T.; Ottolini, D.; Carafoli, E. Neuronal calcium signaling: function and dysfunction. *Cell. Mol. Life Sci.* **2014**, *71* (15), 2787–814.
- (3) Grienberger, C.; Konnerth, A. Imaging calcium in neurons. *Neuron* **2012**, *73* (5), 862–885.
- (4) Wang, W.; Kim, C. K.; Ting, A. Y. Molecular tools for imaging and recording neuronal activity. *Nat. Chem. Biol.* **2019**, *15* (2), 101–110.
- (5) Tian, L.; Akerboom, J.; Schreier, E. R.; Looger, L. L. Neural activity imaging with genetically encoded calcium indicators. *Prog. Brain Res.* **2012**, *196*, 79–94.
- (6) Qian, Y.; Piatkevich, K. D.; Mc Larney, B.; Abdelfattah, A. S.; Mehta, S.; Murdock, M. H.; Gottschalk, S.; Molina, R. S.; Zhang, W.; Chen, Y. A genetically encoded near-infrared fluorescent calcium ion indicator. *Nat. Methods* **2019**, *16* (2), 171–174.
- (7) Nakai, J.; Ohkura, M.; Imoto, K. A high signal-to-noise  $Ca^{2+}$  probe composed of a single green fluorescent protein. *Nat. Biotechnol.* **2001**, *19* (2), 137–141.
- (8) Dana, H.; Sun, Y.; Mohar, B.; Hulse, B. K.; Kerlin, A. M.; Hasseman, J. P.; Tsegaye, G.; Tsang, A.; Wong, A.; Patel, R. High-performance calcium sensors for imaging activity in neuronal populations and microcompartments. *Nat. Methods* **2019**, *16* (7), 649–657.
- (9) Zhao, Y.; Araki, S.; Wu, J.; Teramoto, T.; Chang, Y.-F.; Nakano, M.; Abdelfattah, A. S.; Fujiwara, M.; Ishihara, T.; Nagai, T. An expanded palette of genetically encoded  $Ca^{2+}$  indicators. *Science* **2011**, *333* (6051), 1888–1891.
- (10) Shen, Y.; Nasu, Y.; Shkolnikov, I.; Kim, A.; Campbell, R. E. Engineering genetically encoded fluorescent indicators for imaging of

neuronal activity: Progress and prospects. *Neurosci. Res.* **2020**, *152*, 3–14.

(11) Chen, T.-W.; Wardill, T. J.; Sun, Y.; Pulver, S. R.; Renninger, S. L.; Baohan, A.; Schreiter, E. R.; Kerr, R. A.; Orger, M. B.; Jayaraman, V.; Looger, L. L.; Svoboda, K.; Kim, D. S. Ultrasensitive fluorescent proteins for imaging neuronal activity. *Nature* **2013**, *499* (7458), 295–300.

(12) Tian, L.; Hires, S. A.; Mao, T.; Huber, D.; Chiappe, M. E.; Chalasan, S. H.; Petreanu, L.; Akerboom, J.; McKinney, S. A.; Schreiter, E. R. Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators. *Nat. Methods* **2009**, *6* (12), 875–881.

(13) Miyawaki, A.; Llopis, J.; Heim, R.; McCaffery, J. M.; Adams, J. A.; Ikura, M.; Tsien, R. Y. Fluorescent indicators for Ca<sup>2+</sup> based on green fluorescent proteins and calmodulin. *Nature* **1997**, *388* (6645), 882–887.

(14) Qian, Y.; Rancic, V.; Wu, J.; Ballanyi, K.; Campbell, R. E. A bioluminescent Ca<sup>2+</sup> indicator based on a topological variant of GCaMP6s. *ChemBioChem* **2019**, *20* (4), 516–520.

(15) Akerboom, J.; Chen, T.-W.; Wardill, T. J.; Tian, L.; Marvin, J. S.; Mutlu, S.; Calderón, N. C.; Esposti, F.; Borghuis, B. G.; Sun, X. R.; et al. Optimization of a GCaMP calcium indicator for neural activity imaging. *J. Neurosci.* **2012**, *32* (40), 13819–13840.

(16) Heim, N.; Griesbeck, O. Genetically encoded indicators of cellular calcium dynamics based on troponin C and green fluorescent protein. *J. Biol. Chem.* **2004**, *279* (14), 14280–6.

(17) Stirman, J. N.; Smith, I. T.; Kudinov, M. W.; Smith, S. L. Wide field-of-view, multi-region, two-photon imaging of neuronal activity in the mammalian brain. *Nat. Biotechnol.* **2016**, *34* (8), 857–862.

(18) Ji, N.; Freeman, J.; Smith, S. L. Technologies for imaging neural activity in large volumes. *Nat. Neurosci.* **2016**, *19* (9), 1154.

(19) Kim, T. H.; Zhang, Y.; Lecoq, J.; Jung, J. C.; Li, J.; Zeng, H.; Niell, C. M.; Schnitzer, M. J. Long-term optical access to an estimated one million neurons in the live mouse cortex. *Cell Rep.* **2016**, *17* (12), 3385–3394.

(20) Scott, B. B.; Thiberge, S. Y.; Guo, C.; Tervo, D. G. R.; Brody, C. D.; Karpova, A. Y.; Tank, D. W. Imaging cortical dynamics in GCaMP transgenic rats with a head-mounted widefield microscope. *Neuron* **2018**, *100* (5), 1045–1058.

(21) Cui, G.; Jun, S. B.; Jin, X.; Luo, G.; Pham, M. D.; Lovinger, D. M.; Vogel, S. S.; Costa, R. M. Deep brain optical measurements of cell type-specific neural activity in behaving mice. *Nat. Protoc.* **2014**, *9* (6), 1213–1228.

(22) Ghosh, K. K.; Burns, L. D.; Cocker, E. D.; Nimmerjahn, A.; Ziv, Y.; El Gamal, A.; Schnitzer, M. J. Miniaturized integration of a fluorescence microscope. *Nat. Methods* **2011**, *8* (10), 871.

(23) Li, W.-h.; Fraser, S. E.; Meade, T. J. A Calcium-Sensitive Magnetic Resonance Imaging Contrast Agent. *J. Am. Chem. Soc.* **1999**, *121*, 1413–1414.

(24) Atanasijevic, T.; Shusteff, M.; Fam, P.; Jasanoff, A. Calcium-sensitive MRI contrast agents based on superparamagnetic iron oxide nanoparticles and calmodulin. *Proc. Natl. Acad. Sci. U. S. A.* **2006**, *103* (40), 14707–12.

(25) Angelovski, G.; Fouskova, P.; Mamedov, I.; Canals, S.; Toth, E.; Logothetis, N. K. Smart magnetic resonance imaging agents that sense extracellular calcium fluctuations. *ChemBioChem* **2008**, *9* (11), 1729–34.

(26) Mamedov, I.; Canals, S.; Henig, J.; Beyerlein, M.; Murayama, Y.; Mayer, H. A.; Logothetis, N. K.; Angelovski, G. In vivo characterization of a smart MRI agent that displays an inverse response to calcium concentration. *ACS Chem. Neurosci.* **2010**, *1* (12), 819–28.

(27) Angelovski, G.; Chauvin, T.; Pohmann, R.; Logothetis, N. K.; Toth, E. Calcium-responsive paramagnetic CEST agents. *Bioorg. Med. Chem.* **2011**, *19* (3), 1097–105.

(28) Bar-Shir, A.; Gilad, A. A.; Chan, K. W.; Liu, G.; van Zijl, P. C.; Bulte, J. W.; McMahon, M. T. Metal ion sensing using ion chemical exchange saturation transfer 19F magnetic resonance imaging. *J. Am. Chem. Soc.* **2013**, *135* (33), 12164–7.

(29) Angelovski, G.; Gottschalk, S.; Milosevic, M.; Engelmann, J.; Hagberg, G. E.; Kadane, P.; Andjus, P.; Logothetis, N. K. Investigation of a calcium-responsive contrast agent in cellular model systems: feasibility for use as a smart molecular probe in functional MRI. *ACS Chem. Neurosci.* **2014**, *5* (5), 360–9.

(30) Bar-Shir, A.; Avram, L.; Yaviv-Shoushan, S.; Anaby, D.; Cohen, S.; Segev-Amzaleg, N.; Frenkel, D.; Sadan, O.; Offen, D.; Cohen, Y. Alginate-coated magnetic nanoparticles for noninvasive MRI of extracellular calcium. *NMR Biomed.* **2014**, *27* (7), 774–83.

(31) Garelo, F.; Vibhute, S.; Gunduz, S.; Logothetis, N. K.; Terreno, E.; Angelovski, G. Innovative Design of Ca-Sensitive Paramagnetic Liposomes Results in an Unprecedented Increase in Longitudinal Relaxivity. *Biomacromolecules* **2016**, *17* (4), 1303–11.

(32) MacRenaris, K. W.; Ma, Z.; Krueger, R. L.; Carney, C. E.; Meade, T. J. Cell-Permeable Esterase-Activated Ca(II)-Sensitive MRI Contrast Agent. *Bioconjugate Chem.* **2016**, *27* (2), 465–73.

(33) Preslar, A. T.; Lilley, L. M.; Sato, K.; Zhang, S.; Chia, Z. K.; Stupp, S. I.; Meade, T. J. Calcium-Induced Morphological Transitions in Peptide Amphiphiles Detected by (19)F-Magnetic Resonance Imaging. *ACS Appl. Mater. Interfaces* **2017**, *9* (46), 39890–39894.

(34) Okada, S.; Bartelle, B. B.; Li, N.; Breton-Provencher, V.; Lee, J. J.; Rodriguez, E.; Melican, J.; Sur, M.; Jasanoff, A. Calcium-dependent molecular fMRI using a magnetic nanosensor. *Nat. Nanotechnol.* **2018**, *13* (6), 473–477.

(35) Barandov, A.; Bartelle, B. B.; Williamson, C. G.; Loucks, E. S.; Lippard, S. J.; Jasanoff, A. Sensing intracellular calcium ions using a manganese-based MRI contrast agent. *Nat. Commun.* **2019**, *10* (1), 897.

(36) Du, K.; Thorarinsdottir, A. E.; Harris, T. D. Selective Binding and Quantitation of Calcium with a Cobalt-Based Magnetic Resonance Probe. *J. Am. Chem. Soc.* **2019**, *141* (17), 7163–7172.

(37) Adams, C. J.; Krueger, R.; Meade, T. J. A Multimodal Ca(II) Responsive Near IR-MR Contrast Agent Exhibiting High Cellular Uptake. *ACS Chem. Biol.* **2020**, *15* (2), 334–341.

(38) Gambino, G.; Gambino, T.; Pohmann, R.; Angelovski, G. A ratiometric (19)F MR-based method for the quantification of Ca(2+) using responsive paramagnetic probes. *Chem. Commun. (Cambridge, U. K.)* **2020**, *56* (24), 3492–3495.

(39) Garelo, F.; Gunduz, S.; Vibhute, S.; Angelovski, G.; Terreno, E. Dendritic calcium-sensitive MRI probes: the first low-field relaxometric study. *J. Mater. Chem. B* **2020**, *8* (5), 969–979.

(40) Miller, A. D. C.; Ozbakir, H. F.; Mukherjee, A. Calcium-responsive contrast agents for functional magnetic resonance imaging. *Chemical Physics Reviews* **2021**, *2* (2), 021301.

(41) Shapiro, M. G.; Szablowski, J. O.; Langer, R.; Jasanoff, A. Protein nanoparticles engineered to sense kinase activity in MRI. *J. Am. Chem. Soc.* **2009**, *131* (7), 2484–6.

(42) Shapiro, M. G.; Westmeyer, G. G.; Romero, P. A.; Szablowski, J. O.; Kuster, B.; Shah, A.; Otey, C. R.; Langer, R.; Arnold, F. H.; Jasanoff, A. Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine. *Nat. Biotechnol.* **2010**, *28* (3), 264–70.

(43) Hsieh, V.; Okada, S.; Wei, H.; García-Álvarez, I.; Barandov, A.; Alvarado, S. R.; Ohlendorf, R.; Fan, J.; Ortega, A.; Jasanoff, A. Neurotransmitter-responsive nanosensors for T 2-weighted magnetic resonance imaging. *J. Am. Chem. Soc.* **2019**, *141* (40), 15751–15754.

(44) Brustad, E. M.; Lelyveld, V. S.; Snow, C. D.; Crook, N.; Jung, S. T.; Martinez, F. M.; Scholl, T. J.; Jasanoff, A.; Arnold, F. H. Structure-guided directed evolution of highly selective p450-based magnetic resonance imaging sensors for dopamine and serotonin. *J. Mol. Biol.* **2012**, *422* (2), 245–62.

(45) Hai, A.; Cai, L. X.; Lee, T.; Lelyveld, V. S.; Jasanoff, A. Molecular fMRI of serotonin transport. *Neuron* **2016**, *92* (4), 754–765.

(46) Lee, T.; Cai, L. X.; Lelyveld, V. S.; Hai, A.; Jasanoff, A. Molecular-level functional magnetic resonance imaging of dopaminergic signaling. *Science* **2014**, *344* (6183), 533–535.

(47) Corbin, B. D.; Seeley, E. H.; Raab, A.; Feldmann, J.; Miller, M. R.; Torres, V. J.; Anderson, K. L.; Dattilo, B. M.; Dunman, P. M.; Gerads, R.

Metal chelation and inhibition of bacterial growth in tissue abscesses. *Science* **2008**, 319 (5865), 962–965.

(48) Kehl-Fie, T. E.; Chitayat, S.; Hood, M. I.; Damo, S.; Restrepo, N.; Garcia, C.; Munro, K. A.; Chazin, W. J.; Skaar, E. P. Nutrient metal sequestration by calprotectin inhibits bacterial superoxide defense, enhancing neutrophil killing of *Staphylococcus aureus*. *Cell Host Microbe* **2011**, 10 (2), 158–64.

(49) Zackular, J. P.; Chazin, W. J.; Skaar, E. P. Nutritional immunity: S100 proteins at the host-pathogen interface. *J. Biol. Chem.* **2015**, 290 (31), 18991–18998.

(50) Brophy, M. B.; Nolan, E. M. Manganese and microbial pathogenesis: sequestration by the Mammalian immune system and utilization by microorganisms. *ACS Chem. Biol.* **2015**, 10 (3), 641–651.

(51) Brunjes Brophy, M.; Nakashige, T. G.; Gaillard, A.; Nolan, E. M. Contributions of the S100A9 C-terminal tail to high-affinity Mn (II) chelation by the host-defense protein human calprotectin. *J. Am. Chem. Soc.* **2013**, 135 (47), 17804–17817.

(52) Damo, S. M.; Kehl-Fie, T. E.; Sugitani, N.; Holt, M. E.; Rathi, S.; Murphy, W. J.; Zhang, Y.; Betz, C.; Hench, L.; Fritz, G. Molecular basis for manganese sequestration by calprotectin and roles in the innate immune response to invading bacterial pathogens. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, 110 (10), 3841–3846.

(53) Zygiel, E. M.; Nolan, E. M. Transition Metal Sequestration by the Host-Defense Protein Calprotectin. *Annu. Rev. Biochem.* **2018**, 87, 621–643.

(54) Korndörfer, I. P.; Brueckner, F.; Skerra, A. The crystal structure of the human (S100A8/S100A9) 2 heterotetramer, calprotectin, illustrates how conformational changes of interacting  $\alpha$ -helices can determine specific association of two EF-hand proteins. *J. Mol. Biol.* **2007**, 370 (5), 887–898.

(55) Gagnon, D. M.; Brophy, M. B.; Bowman, S. E.; Stich, T. A.; Drennan, C. L.; Britt, R. D.; Nolan, E. M. Manganese binding properties of human calprotectin under conditions of high and low calcium: X-ray crystallographic and advanced electron paramagnetic resonance spectroscopic analysis. *J. Am. Chem. Soc.* **2015**, 137 (8), 3004–16.

(56) Hayden, J. A.; Brophy, M. B.; Cunden, L. S.; Nolan, E. M. High-affinity manganese coordination by human calprotectin is calcium-dependent and requires the histidine-rich site formed at the dimer interface. *J. Am. Chem. Soc.* **2013**, 135 (2), 775–87.

(57) Caravan, P.; Farrar, C. T.; Frullano, L.; Uppal, R. Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. *Contrast Media Mol. Imaging* **2009**, 4 (2), 89–100.

(58) Li, N.; Jasanoff, A. Local and global consequences of reward-evoked striatal dopamine release. *Nature* **2020**, 580 (7802), 239–244.

(59) Mukherjee, A.; Wu, D.; Davis, H. C.; Shapiro, M. G. Non-invasive imaging using reporter genes altering cellular water permeability. *Nat. Commun.* **2016**, 7 (1), 13891.

(60) Albaugh, D. L.; Salzwedel, A.; Van Den Berge, N.; Gao, W.; Stuber, G. D.; Shih, Y.-Y. I. Functional Magnetic Resonance Imaging of Electrical and Optogenetic Deep Brain Stimulation at the Rat Nucleus Accumbens. *Sci. Rep.* **2016**, 6 (1), 31613.

(61) Rao, W.; Peng, C.; Zhang, L.; Su, N.; Wang, K.; Hui, H.; Dai, S.-h.; Yang, Y.-f.; Luo, P.; Fei, Z. Homer1a attenuates glutamate-induced oxidative injury in HT-22 cells through regulation of store-operated calcium entry. *Sci. Rep.* **2016**, 6 (1), 33975.

(62) Zhang, X.; Qiao, Z.; Liu, N.; Gao, L.; Wei, L.; Liu, A.; Ma, Z.; Wang, F.; Hou, S.; Li, J.; Shen, H. Stereotypical patterns of epileptiform calcium signal in hippocampal CA1, CA3, dentate gyrus and entorhinal cortex in freely moving mice. *Sci. Rep.* **2019**, 9 (1), 4518.

(63) Daoust, A.; Barbier, E. L.; Bohic, S.; Stupar, V.; Maunoir-Regimbal, S.; Fauvel, F. Impact of manganese on the hippocampus metabolism in the context of MEMRI: a proton HRMAS MRS study. *Toxicol. Res.* **2015**, 4 (2), 376–384.

(64) Silva, A. C.; Lee, J. H.; Aoki, I.; Koretsky, A. P. Manganese-enhanced magnetic resonance imaging (MEMRI): methodological and practical considerations. *NMR Biomed.* **2004**, 17 (8), 532–543.

(65) Jacobs, K. E.; Behera, D.; Rosenberg, J.; Gold, G.; Moseley, M.; Yeomans, D.; Biswal, S. Oral manganese as an MRI contrast agent for

the detection of nociceptive activity. *NMR Biomed.* **2012**, 25 (4), 563–569.

(66) Atanasijevic, T.; Bouraoud, N.; McGavern, D. B.; Koretsky, A. P. Transcranial manganese delivery for neuronal tract tracing using MEMRI. *NeuroImage* **2017**, 156, 146–154.

(67) Silva, A. C.; Lee, J. H.; Aoki, I.; Koretsky, A. P. Manganese-enhanced magnetic resonance imaging (MEMRI): methodological and practical considerations. *NMR Biomed.* **2004**, 17 (8), 532–43.

(68) Koretsky, A. P.; Silva, A. C. *Manganese-enhanced magnetic resonance imaging (MEMRI)*; Wiley Online Library: 2004.

(69) Malkova, N. V.; Gallagher, J. J.; Collin, Z. Y.; Jacobs, R. E.; Patterson, P. H. Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia. *Proc. Natl. Acad. Sci. U. S. A.* **2014**, 111 (24), E2492–E2500.

(70) Lu, H.; Xi, Z.-X.; Gitajn, L.; Rea, W.; Yang, Y.; Stein, E. A. Cocaine-induced brain activation detected by dynamic manganese-enhanced magnetic resonance imaging (MEMRI). *Proc. Natl. Acad. Sci. U. S. A.* **2007**, 104 (7), 2489–2494.

(71) Bartelle, B. B.; Mana, M. D.; Suero-Abreu, G. A.; Rodriguez, J. J.; Turnbull, D. H. Engineering an effective Mn-binding MRI reporter protein by subcellular targeting. *Magn. Reson. Med.* **2015**, 74 (6), 1750–1757.

(72) Bartelle, B. B.; Szulc, K. U.; Suero-Abreu, G. A.; Rodriguez, J. J.; Turnbull, D. H. Divalent metal transporter, DMT1: A novel MRI reporter protein. *Magn. Reson. Med.* **2013**, 70 (3), 842–850.

(73) Fanali, G.; Cao, Y.; Ascenzi, P.; Fasano, M. Mn (II) binding to human serum albumin: a <sup>1</sup>H-NMR relaxometric study. *J. Inorg. Biochem.* **2012**, 117, 198–203.

(74) Liu, X.; Lopez, P. A.; Giessen, T. W.; Giles, M.; Way, J. C.; Silver, P. A. Engineering Genetically-Encoded Mineralization and Magnetism via Directed Evolution. *Sci. Rep.* **2016**, 6 (1), 38019.

(75) Matsumoto, Y.; Chen, R.; Anikeeva, P.; Jasanoff, A. Engineering intracellular biomineralization and biosensing by a magnetic protein. *Nat. Commun.* **2015**, 6 (1), 8721.

(76) Brustad, E. M.; Lelyveld, V. S.; Snow, C. D.; Crook, N.; Jung, S. T.; Martinez, F. M.; Scholl, T. J.; Jasanoff, A.; Arnold, F. H. Structure-Guided Directed Evolution of Highly Selective P450-Based Magnetic Resonance Imaging Sensors for Dopamine and Serotonin. *J. Mol. Biol.* **2012**, 422 (2), 245–262.

(77) Xue, S.; Yang, H.; Qiao, J.; Pu, F.; Jiang, J.; Hubbard, K.; Hekmatyar, K.; Langley, J.; Salarian, M.; Long, R. C. Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, 112 (21), 6607–6612.